Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment

The first randomized trial of adjuvant treatment with checkpoint inhibitor in stage II melanoma reported a significant reduction in risk of tumor recurrence. This study evaluates two independent data sets to further document survival probabilities for patients with primary stage I and II melanoma. P...

Descripción completa

Detalles Bibliográficos
Autores principales: Garbe, Claus, Keim, Ulrike, Amaral, Teresa, Berking, Carola, Eigentler, Thomas K., Flatz, Lukas, Gesierich, Anja, Leiter, Ulrike, Stadler, Rudolf, Sunderkötter, Cord, Tüting, Thomas, Utikal, Jochen, Wollina, Uwe, Zimmer, Lisa, Zouboulis, Christos C., Ascierto, Paolo A., Eggermont, Alexander M.M., Grob, Jean-Jacques, Hauschild, Axel, Sekulovic, Lidija Kandolf, Long, Georgina V., Luke, Jason J., Michielin, Olivier, Peris, Ketty, Schadendorf, Dirk, Kirkwood, John M., Lorigan, Paul C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649277/
https://www.ncbi.nlm.nih.gov/pubmed/35709414
http://dx.doi.org/10.1200/JCO.22.00202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649277/
https://www.ncbi.nlm.nih.gov/pubmed/35709414
http://dx.doi.org/10.1200/JCO.22.00202

Ejemplares similares